Stay updated with breaking news from Receptor Type. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in...
/PRNewswire/ -- The newly published report titled "Global Cannabinoid Derived Pharmaceutical Market – By Trends, Industry Competition Analysis, Pipeline...
JERSEY CITY, N.J., Feb. 3, 2022 /PRNewswire/ -- The newly published report titled "Global Cannabinoid Derived Pharmaceutical Market - By Trends, Industry Competition Analysis, Pipeline Analysis
Share this article Share this article SUZHOU, China, July 14, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces that the first US patient has been dosed in the global Phase I clinical trial of PD-L1/TGF-β bi-functional antibody TST005. TST005 is the second bi-functional anti-PD-L1 and TGF-β trap fusion protein entering the global clinical stage. It simultaneously targets two immuno-suppressive pathways, transfo...
Investigating the prognosis value of EDNRA expression and its correlation with immune infiltrates in patients with stomach adenocarcinoma